Opioid overdose has become a major problem for governments in developing and developed countries, especially in the United States and the United Kingdom. With the surging number of governments legalizing prescription opioids, the risk of opioid abuse too rises.
This has pushed the demand for alexipharmic drugs. The alexipharmic drug market valuation is estimated to be a staggering US$ 3.80 billion in 2024 and is slated to reach US$ 6.50 billion by the end of 2034, growing at a decent CAGR of 5.40%.
| Attributes | Details |
|---|---|
| Market Value for 2024 | US$ 3.80 billion |
| Projected Market Value for 2034 | US$ 6.50 billion |
| Value-based CAGR of the Market for 2024 to 2034 | 5.40% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The rising disposable income among the younger generation and their desire to lead a Western lifestyle has naturally generated an excellent demand for medications and solutions that relieve people from alcohol or opioid overdose.
The growth rates of the alcohol use disorder treatment market and the alcoholic hepatitis treatment market, along with their challenges and ongoing trends, have been jotted down below.
Based on these analytics, it can be confidently projected that the alcoholic hepatitis treatment market is likely to have a more promising future in comparison to the other two.
Alexipharmic Drug Market:
| Attributes | Alexipharmic Drug Market |
|---|---|
| Value-based CAGR (2024 to 2034) | 5.40% |
| Projected Market Value (2024) | US$ 3.80 billion |
| Growth Factor | Growing number of people, especially those living in urban and semi-urban parts of the world, are realizing the benefits of these counterpoisons primarily through social media and government campaigns |
| Restraint | Lack of availability of these drugs in underdeveloped and developing areas due to low consumer demand and high price |
| Trend | Companies collaborating with government bodies to effectively spread awareness about alexipharmic drugs |
Alcohol Use Disorder Treatment Market:
| Attributes | Alcohol Use Disorder Treatment Market |
|---|---|
| Value-based CAGR (2024 to 2034) | 6.4% |
| Growth Factor | Increased government support, such as an increase in initiatives to improve consumer awareness about drug addiction, is likely to drive the market |
| Restraint | Lack of knowledge of viable pharmacological therapy for AUD, particularly in emerging and underdeveloped nations |
| Trend | Effective marketing strategies through social media campaigns and television ads increase the significance of these treatments |
Alcoholic Hepatitis Treatment Market:
| Attributes | Alcoholic Hepatitis Treatment Market |
|---|---|
| Value-based CAGR (2024 to 2034) | 6.5% |
| Growth Factor | As more people consume alcohol, and in higher quantities, the incidence of liver diseases such as alcoholic hepatitis has been on rise |
| Restraints |
|
| Trends | Advancements in technology in liver disease treatment are expected to provide new and improved treatment options for patients with alcoholic hepatitis |
Principal Consultant
Alexipharmic drugs are used for various purposes, such as opioid overdose, alcohol overdose, benzodiazepine overdose, etc. Among these, opioid overdose is in line to hold a majority market share of 39% in 2024.
| Attributes | Details |
|---|---|
| Application | Opioid Overdose |
| Market Share (2024) | 39% |
Increased awareness among the general population about the opioid crisis and the importance of having access to naloxone and other counterpoisons have significantly impacted the market growth.
The effectiveness of counterpoisons like naloxone is also pushing consumers to prefer them for opioid overdose situations. With time and tide, the stigma around the use of counterpoisons has also made consumers more comfortable in using these drugs without being frowned upon.
With the growing demand for counterpoisons in the general public, manufacturers are targeting various distribution channels for the sales of these drugs. Based on this, hospital pharmacies are poised to hold a majority share of 42% in this market in 2024.
| Attributes | Details |
|---|---|
| Distribution Channel | Hospital Pharmacies |
| Market Share (2024) | 42% |
Hospital pharmacies are the number one destination for counterpoisons as they are often the first point of contact for individuals experiencing severe drug overdoses. Apart from this, medical professionals prescribe counterpoisons, which are seldom found outside of hospital pharmacies.
These hospital pharmacies are also generating huge demand for these drugs as they are closely integrated with other clinical services, including emergency departments and intensive care units.
| Countries | CAGR (2024 to 2034) |
|---|---|
| South Korea | 8.00% |
| Japan | 7.10% |
| United Kingdom | 6.70% |
| China | 6.30% |
| United States | 5.70% |
The market in South Korea is slated to grow at a CAGR of 8.00% through 2034. The government has been actively implementing various initiatives to mitigate the rising cases of alcohol and opioid overuse. For this, they have been promoting various counterpoisons such as naloxone.
The government’s support in the form of awareness campaigns, training, and accessibility, has created a conducive environment for the increasing adoption of counterpoisons in the country. The market is also growing in South Korea due to the increasing availability of these drugs across various distribution channels.
The market in Japan is a promising one. It is anticipated to grow at a CAGR of 7.10% through 2034. Japan, in the last few years, has been reporting a substantial rise in opioid prescription rates, thanks to the influence of Western lifestyles on the younger generations in the country. This has created unprecedented demand for these drugs in the country.
The consumption of these drugs has also touched the skies as there has been a shift in public attitudes towards drug addiction. With increasing recognition of the need for harm reduction measures such as naloxone distribution programs, the market is set to benefit.
The market in the United Kingdom is very likely to flourish in the coming years. The market is expected to grow at a CAGR of 6.70% through 2034. According to a survey, the opioid crisis in the United Kingdom has reached its all-time peak as opiate-related drug poisoning deaths have increased by 388% since 1993 in England and Wales.
This has significantly increased the prominence of these drugs in the United Kingdom as more people seek medications and prescriptions during emergencies associated with opioid abuse. Community distribution programs conducted by the public as well as private entities are also benefiting the consumption of these drugs in the country.
The market in China is also among the lucrative ones. It is expected to grow at a CAGR of 6.30% through 2034. The government has made strict rules and regulations regarding the manufacturing, possession, and distribution of counterpoisons in the country.
This has instilled a sense of trust in these medications among the general population in China, which is appreciably increasing the consumption of these drugs in the country. The consumption of these drugs in the Chinese marketplace is observed to be more in the urban and semi-urban settings, as compared to the rural ones.
The United States alexipharmic drug market is a lucrative one. It is estimated to grow at a CAGR of 5.70% through 2034. The country is currently facing the problem of opioid addiction among the general populace.
Each year, more than 15 million people in the United States consume prescription opioids. This automatically generates huge demand for these drugs in the country as the chances of overdose are very high.
Increasing awareness among the people, coupled with rising disposable income, is a key reason for the market’s growth in the country. Modern and sophisticated infrastructure and reduced stigma regarding the use of counterpoisons among individuals are also responsible for the growth of this market in the country.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The alexipharmic drug market is filled with a multitude of companies vying for international dominance in the marketplace. These companies, being in the pharma industry for a prolonged period of time, have extended their market reach beyond international borders.
The advent of online medicine platforms, telemedicine, and last-mile-delivery services in developed and developing countries has also helped the market to flourish in the past few years.
Recent Developments
The market is expected to be worth US$ 3.80 billion in 2024.
The market is expected to reach US$ 6.50 billion by 2034.
The market is in line to grow at a CAGR of 5.40% from 2024 to 2034.
Alkermes, Inc., B. Braun Melsungen AG, Bausch Health Companies Inc., Emergent BioSolutions, and Ethypharm S. A. are some of the major players in the market.
The valuation for the alexipharmic drug market in 2023 was US$ 3.60 billion.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Manufacturer 3.5.1.2. Mid-Level Participants (Traders) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Application, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Application, 2024 to 2034 5.3.1. Alcoholic Overdose 5.3.2. Opioid Overdose 5.3.3. Benzodiazepine Overdose 5.3.4. Others 5.4. Y-o-Y Growth Trend Analysis By Application, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Application, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Distribution Channel, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034 6.3.1. Hospital Pharmacies 6.3.2. Retail Pharmacies 6.3.3. Online Pharmacies 6.3.4. Others 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Region, 2019 to 2023 7.3. Current Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 8.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 8.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Application 8.2.3. By Distribution Channel 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Application 8.3.3. By Distribution Channel 8.4. Key Takeaways 9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Application 9.2.3. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Application 9.3.3. By Distribution Channel 9.4. Key Takeaways 10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Application 10.2.3. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Application 10.3.3. By Distribution Channel 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Application 11.2.3. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Application 11.3.3. By Distribution Channel 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Application 12.2.3. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Application 12.3.3. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Application 13.2.3. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Application 13.3.3. By Distribution Channel 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Application 14.2.3. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Application 14.3.3. By Distribution Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2023 15.1.2.1. By Application 15.1.2.2. By Distribution Channel 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2023 15.2.2.1. By Application 15.2.2.2. By Distribution Channel 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2023 15.3.2.1. By Application 15.3.2.2. By Distribution Channel 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2023 15.4.2.1. By Application 15.4.2.2. By Distribution Channel 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2023 15.5.2.1. By Application 15.5.2.2. By Distribution Channel 15.6. UK 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2023 15.6.2.1. By Application 15.6.2.2. By Distribution Channel 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2023 15.7.2.1. By Application 15.7.2.2. By Distribution Channel 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2023 15.8.2.1. By Application 15.8.2.2. By Distribution Channel 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2023 15.9.2.1. By Application 15.9.2.2. By Distribution Channel 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2023 15.10.2.1. By Application 15.10.2.2. By Distribution Channel 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2023 15.11.2.1. By Application 15.11.2.2. By Distribution Channel 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2023 15.12.2.1. By Application 15.12.2.2. By Distribution Channel 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2023 15.13.2.1. By Application 15.13.2.2. By Distribution Channel 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2023 15.14.2.1. By Application 15.14.2.2. By Distribution Channel 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2023 15.15.2.1. By Application 15.15.2.2. By Distribution Channel 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2023 15.16.2.1. By Application 15.16.2.2. By Distribution Channel 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2023 15.17.2.1. By Application 15.17.2.2. By Distribution Channel 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2023 15.18.2.1. By Application 15.18.2.2. By Distribution Channel 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2023 15.19.2.1. By Application 15.19.2.2. By Distribution Channel 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2023 15.20.2.1. By Application 15.20.2.2. By Distribution Channel 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2023 15.21.2.1. By Application 15.21.2.2. By Distribution Channel 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2023 15.22.2.1. By Application 15.22.2.2. By Distribution Channel 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2023 15.23.2.1. By Application 15.23.2.2. By Distribution Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Application 16.3.3. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Alkermes, Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. B. Braun Melsungen AG 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Bausch Health Companies Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Emergent BioSolutions 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Ethypharm S. A. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Fresenius SE & Co. KGaA 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Hikma Pharmaceuticals 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. Merck & Co., Inc. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. Mylan N.V. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. SGPharma Pvt. Ltd. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Alexipharmic Drug Market
